Tag: Acurate neo

Novel repositionable TAVI valve has acceptable early clinical outcomes

A new study indicates that the Meridian transcatheter aortic valve implantation (TAVI) valve (HLT) is associated with a 30-day mortality rate of 8% and...

Lotus Edge becomes third TAVI device on US market

Boston Scientific has received US FDA approval for its Lotus Edge transcatheter aortic valve implantation (TAVI) system. It is approved for patients with severe...

ADVERTORIAL: Unique design and features of the ACURATE neo (TM) enable...

This content is only for readers outside of the US as it discusses a device that is not FDA approved. Results from the SAVI-TF Registry1,...

PCR LV 2018: Favourable outcomes for next-generation Acurate neo2 TAVI system

A new study evaluating the safety and performance of the Acurate neo2 (Boston Scientific) transcatheter aortic valve implantation (TAVI) system demonstrated a high procedural...

Boston Scientific successfully opposes Edwards Lifesciences Corporation’s European patent EP 2,399,550...

According to a press release, Boston Scientific has, along with several other opponents, successfully opposed Edwards Lifesciences Corporation's European patent EP 2,399,550 (550) in...

UK Court of Appeal dismisses Edwards Lifesciences’ appeal against Sapien 3...

Acurate neo Boston Scientific has announced the UK Court of Appeal  dismissed Edwards Lifesciences’ appeal and upheld a prior court decision that Edwards’...